Silencing HCCR2 expression inhibits the proliferation of leukemia cells by inducing apoptosis and promoting cell cycle arrest

Qiao,Shu-Kai; Ren,Han-Yun; Shi,Yong-Jin; Liu,Wei

doi:10.3892/ijmm.2013.1518

Silencing HCCR2 expression inhibits the proliferation of leukemia cells by inducing apoptosis and promoting cell cycle arrest

Authors:
- Shu-Kai Qiao
- Han-Yun Ren
- Yong-Jin Shi
- Wei Liu
View Affiliations

Affiliations: Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. China
Published online on: October 8, 2013 https://doi.org/10.3892/ijmm.2013.1518
Pages: 1373-1379

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The human cervical cancer oncogene (HCCR2) has been found to be overexpressed in a variety of human malignant tumors cells, and its function is related to cell cycle progression and survival. However, the molecular mechanisms of action of HCCR2 in leukemia remain unclear. In this study, we used the RNA interference strategy to investigate the effects of HCCR2 knockdown in the K562 leukemia cell line, and to explore the potential mechanisms involved. Following transfection with small interfering RNA (siRNA) targeting HCCR2 (HCCR2-siRNA), we examined the effects of HCCR2 knockdown on cell morphology, cell proliferation, cell cycle progression and apoptosis in K562 cells. Morphological changes were evaluated by Wright-Giemsa staining. Cell cycle progression and apoptosis were measured by flow cytometry. The expression levels of genes related to the cell cycle and apoptosis were detected by quantitative RT-PCR (qRT-PCR) and western blot analysis. HCCR2 expression at the mRNA and protein level was significantly decreased following transfection with plasmids expressing HCCR2-siRNA. Silencing HCCR2 expression significantly suppressed cell proliferation, induced G1 cell cycle arrest and promoted the apoptosis of K562 cells. Additionally, we found that the expression of Bax, p53 and p21 was significantly increased, while Bcl-2 expression was significantly decreased in the HCCR2-siRNA-transfected cells. However, the expression of p27 was not affected. These results suggest that the HCCR2 gene plays an important role in the tumorigenesis of leukemia, thus making it an attractive therapeutic target for acute leukemia.

View Figures

View References

1	Ferrara F and Schiffer CA: Acute myeloid leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
2	Inaba H, Greaves M and Mullighan CG: Acute lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hamilton BK and Copelan EA: Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia. Stem Cells. 30:1581–1586. 2012. View Article : Google Scholar : PubMed/NCBI
4	Khaled SK, Thomas SH and Forman SJ: Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr Opin Oncol. 24:182–190. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ungewickell A and Medeiros BC: Novel agents in acute myeloid leukemia. Int J Hematol. 96:178–185. 2012. View Article : Google Scholar
6	Roboz GJ: Current treatment of acute myeloid leukemia. Curr Opin Oncol. 24:711–719. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kimby E, Nygren P and Glimelius B: A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol. 40:231–252. 2001. View Article : Google Scholar : PubMed/NCBI
8	Ko J, Lee YH, Hwang SY, et al: Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization. Oncogene. 22:4679–4689. 2003. View Article : Google Scholar : PubMed/NCBI
9	Chung YJ and Kim JW: Novel oncogene HCCR: its diagnostic and therapeutic implications for cancer. Histol Histopathol. 20:999–1003. 2005.PubMed/NCBI
10	Ko J, Shin SM, Oh YM, Lee YS, Ryoo ZY, Lee YH, Na DS and Kim JW: Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice. Oncogene. 23:1950–1953. 2004. View Article : Google Scholar : PubMed/NCBI
11	Yoon SK, Lim NK, Ha SA, et al: The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res. 64:5434–5441. 2004. View Article : Google Scholar : PubMed/NCBI
12	Jung SS, Park HS, Lee IJ, et al: The HCCR oncoprotein as a biomarker for human breast cancer. Clin Cancer Res. 11:7700–7708. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ha SA, Lee YS, Shin SM, et al: Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. BMC Cancer. 9:512009. View Article : Google Scholar : PubMed/NCBI
14	Ha SA, Shin SM, Lee YJ, et al: HCCRBP-1 directly interacting with HCCR-1 induces tumorigenesis through P53 stabilization. Int J Cancer. 122:501–508. 2008. View Article : Google Scholar : PubMed/NCBI
15	Qiao SK, Guo XN, Xu SR and Wang Y: The expression and clinical prognostic value of HCCR genes in patients with acute leukemia. Chin Journal Hematol. 7:481–483. 2010.(In Chinese).
16	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
17	Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R and Min WP: RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant. 4:1227–1236. 2004. View Article : Google Scholar : PubMed/NCBI
18	Leung RK and Whittaker PA: RNA interference: from gene silencing to gene- specific therapeutics. Pharmacol Ther. 107:222–239. 2005. View Article : Google Scholar : PubMed/NCBI
19	Takeshita F and Ochiya T: Therapeutic potential of RNA interference against cancer. Cancer Sci. 97:689–696. 2006. View Article : Google Scholar : PubMed/NCBI
20	Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC and Hainaut P: Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 16:1–12. 2009. View Article : Google Scholar
21	Wang B, Xiao Z and Ren EC: Redefining the p53 response element. Proc Natl Acad Sci USA. 106:14373–14378. 2009. View Article : Google Scholar : PubMed/NCBI
22	Peller S and Rotter V: TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 21:277–284. 2003. View Article : Google Scholar : PubMed/NCBI
23	Janssen A, Schiffmann S, Birod K, Maier TJ, Wobst I, Geisslinger G and Grösch S: p53 is important for the anti-proliferative effect of ibuprofen in colon carcinoman cells. Biochem Biophys Res Commun. 365:698–703. 2008. View Article : Google Scholar : PubMed/NCBI
24	Guo J, Yang L, Zhang Y, Wang J, Wan S, Xia S, Yang S, Wang R and Fang D: Silencing of the HCCR2 gene induces apoptosis and suppresses the aggressive phenotype of hepatocellular carcinoma cells in culture. J Gastrointest Surg. 15:1807–1813. 2011. View Article : Google Scholar : PubMed/NCBI
25	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
26	Warfel NA and El-Deiry WS: p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013.PubMed/NCBI
27	Stivala LA, Cazzalini O and Prosperi E: The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs. Curr Cancer Drug Targets. 12:85–96. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kizildag S, Ates H and Kizildag S: Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann Hematol. 89:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
29	Cmielová J and Rezáčová M: p21Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J Cell Biochem. 112:3502–3506. 2011.PubMed/NCBI
30	Wang X, Gao P, Long M, Lin F, Wei JX, Ren JH, Yan L, He T, Han Y and Zhang HZ: Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 28:1225–1254. 2011. View Article : Google Scholar : PubMed/NCBI
31	Coqueret O: New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
32	Tomek M, Akiyama T and Dass CR: Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J Pharm Pharmacol. 64:1695–1702. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yin C, Knudson CM, Korsmeyer SJ and Van Dyke T: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:637–640. 1997. View Article : Google Scholar : PubMed/NCBI
34	Chiu TL and Su CC: Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-κBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 23:469–475. 2009.PubMed/NCBI